
This content was machine translated.
About RNATICS GmbH
RNATICS develops medicines based on short nucleic acid molecules, so-called oligonucleotides, that target disease-causing RNAs in tissue-resident macrophages. This novel delivery mechanism enables access to organs that have previously been inaccessible for nucleic acid therapies, opening up significant therapeutic potential in many diseases. We plan to start the first clinical trial (Phase I) of our lead candidate, RCS-21, for the treatment of fibrotic lung disease following viral infections (e.g. COVID-19) in spring 2024.
More like this
Discover more articles, startups, and events from the ecosystem

Ecosystem
European Founder Report: Europe’s Startup Boom Has a Funding Problem
25.09.26
4 Min.

Ecosystem
17 Munich Institutions Found Women Entrepreneurs Alliance
25.09.26
3 Min.

Deals
AI Security Startup Kontext Raises €3.5 Million for Secure AI Agents
24.09.26
4 Min.

Pitch Event
Media Startup Night Vol. 7 @Bits & Pretzels
September 28, 2026
06:30 PM – 10:30 PM
Media Lab Bayern (at the Medien.Bayern GmbH Office), Munich
Conference
14th Bavarian CSR Day: What really counts now
September 29, 2026
02:00 PM – 07:00 PM
IHK für München und Oberbayern, München